A vast number of mutations, including those of TERT, BRAF, NRAS, PTEN, and CDKN2A, have been linked to the malignant transformation of melanocytes in subgroups of primary melanomas [2–4], rendering therapeutic approaches challenging. This evidence concerns the gene BRAF and melanoma.